A Phase 1/2 study of filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma

BACKGROUND: Filanesib (ARRY-520) is a highly selective inhibitor of kinesin spindle protein, which has shown preclinical anti-myeloma activity. METHODS: This open-label Phase 1/2 study determined the maximum tolerated dose (MTD) of filanesib administered on Days 1 and 2 of 14-day cycles in patients...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer
Hoofdauteurs: Shah, Jatin J., Kaufman, Jonathan L., Zonder, Jeffrey A., Cohen, Adam D., Bensinger, William I., Hilder, Brandi, Rush, Selena, Walker, Duncan, Tunquist, Brian, Litwiler, Kevin, Ptaszynski, Mieke, Orlowski, Robert Z., Lonial, Sagar
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2017
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5856158/
https://ncbi.nlm.nih.gov/pubmed/28817190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30892
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items